Volume : 10, Issue : 08, August – 2023
Title:
40.RISPERIDONE LIQUISOLID COMPACTS–FORMULATION AND EVALUATION
Authors :
Kulkarni Rupanjali , Devara Raj kumar
Abstract :
Risperidone is an atypical antipsychotic agent used for serious brain illness like schizophrenia. However low aqueous solubility of this risperidone leads to its lower dissolution and thus lower bioavailability. Therefore, the development of risperidone liquisolid compacts was done with an aim to improve its dissolution rate via increasing the solubility of the drug. This results in improvement of its oral bioavailability. Aim of the present study was to augment the dissolution rate of Risperidone, thus increasing the oral bioavailability of poorly soluble drug. Preformulation studies like flow properties. The Fourier Transform Infrared spectroscopy (FTIR) results revealed that, there was no interaction among excipients (carrier, coating material, non-volatile solvent), and the drug risperidone. In-vitro drug dissolution studies showed improved in drug release of risperidone compared to pure drug. So, PEG 400, PG could be economic substitute as dissolution enhancing agent. It was determined that first order kinetics provided the greatest fit for the release data based on mathematical information obtained from models. The diffusion-controlled release mechanism is described by the Higuchi equation; the risperidone compacts’ diffusion exponent indicating non-Fickian diffusion. Among PEG 400, PG, PEG 400 in 1:1 ratio with risperidone (F11, F12, F16, F17, F18) using carrier’s spray dried lactose and syloid 244FP in ratio’s of 10:1 and 20:1 with coating material aerosoil 200 was showing best results. F18 best among the successful formulations with highest drug release rate was compared with marketed preparation and results were better than marketed preparation.
Keywords: Risperidone, liquisolid compacts, FTIR, Carriers, Preformulation ,In-vitro drug release.
Cite This Article:
Please cite this article in press Kulkarni Rupanjali et al, Risperidone Liquisolid Compacts–Formulation And Evaluatio , Indo Am. J. P. Sci, 2023; 10 (08).
Number of Downloads : 10
References:
1. Alonzo D.E., Zhang G.G., Zhou D., Gao Y., Taylor L.S. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm. Res. 2010; 27:608–618.
2. Avachat A.M., Parpani S.S. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf., B. 2015;126:87–97.
3. Burra S., Yamsani M., Vobalaboina V. The liquisolid technique: an overview. Brazil. J. Pharm. Sci. 2011; 47:475–482.
4. Chella N., Narra N., Rama Rao T. Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan. J. Drug Delivery. 2014; 2014:1–10.
5. Chella N., Shastri N., Tadikonda R.R. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm. Sin. B. 2012; 2:502–508.
6. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanodrug. 2010; 5:11–23.
7. Elkordy A.A., Tan X.N., Essa E.A. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur. J. Pharm. Biopharm. 2013; 83:203–223.
8. Hentzschel C., Alnaief M., Smirnova I., Sakmann A., Leopold C. Enhancement of griseofulvin release from liquisolid compacts. Eur. J. Pharm. Biopharm. 2012; 80:130–135.
9. Javadzadeh Y., Jafari-Navimipour B., Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine) Int. J. Pharm. 2007;341:26–34.
10. Patel G.V., Patel V.B., Pathak A., Rajput S.J. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Dev. Ind. Pharm. 2014; 40:80–91.
11. Sathigari S.K., Radhakrishnan V.K., Davis V.A., Parsons D.L., Babu R.J. Amorphous-state characterization of efavirenz—polymer hot-melt extrusion systems for dissolution enhancement. J. Pharm. Sci. 2012; 101:3456–3464.
12. Siepmann J., Siepmann F. Mathematical modeling of drug dissolution. Int. J. Pharm. 2013; 453:12–24.
13. Wu L., Zhang J., Watanabe W. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 2011; 63:456–469.
14. Seth NS, “Formulation and evaluation of solid dispersion of olanzepine,” Int. J. Pharm. Sci. Res.2011, v.2 (2): p.691-697.
15. Ramadevi Korni, Susheela Voodikala, C S R Gonugunta and Vijayaratna Jayanti. Liquisolid technique: An approach to enhance the dissolution rate of olanzapine. Indian J Pharm Sci., 2018; 80(6): 1003-1010.
16. 16.Vinod Kumar Yata Ananda Kumar Chettupalli , Ramkoteswar Rao Amara , Padmanabha Rao Amarachinta , Ram Mohan Manda , Baba Shankar Rao GarigeFormulation and Evaluation of Poly Herbal Liqui-Solid Compact for its Anti-Inflammatory Effect,2022,Biointerface Research in Applied Chemistry12(3),3883-3899.
17. Monali Kalbhor, Ashok Bhosale, Ravindra Patil, Sujit Kakade. Formulation and evaluation of telmisartan liquisolid compact tablet. Int J Pharmacy and Pharma Res., 2017; 9(4): 152-182
18. Anand D. Savkare, Malavi R. Bhavsar, Vishal D. Gholap and Pooja M. Kukkar liquisolid technique: a review. Int J Pharma Sci and Res., 2017; 8(7): 2768-2775.
19. Amol S. Deshmukh, Vinod G. Mahale, Vijay R Mahajan. Liquisolid compact techniques: A Rev. Res J of Pharm Dosage Forms and Tech, 2014; 6(3): 161-166.
20. Sahir V, Ghuge N, Bakde B V. Liquisolid compact: a new technique for enhancement of drug dissolution. Int J Pharm Res Dev., 2012; 3(1): 1-5.